Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 1/20 | 0.72 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.72 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.72 |
| ▸ | FYN | P06241 | 5/20 | 0.64 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | IGF1R | P08069 | 2/20 | 0.49 |
| ▸ | RAD52 | P43351 | 4/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679053 | 0.93 | PRKD3 (0.70) | PRKD3PRKD1PRKD2FYNMAP4K4 | |
| SCHEMBL1679747 | 0.93 | PRKD3 (0.70) | PRKD3PRKD1PRKD2FYNMAP4K4 | |
| SCHEMBL1679463 | 0.92 | PRKD3 (0.69) | PRKD3PRKD1PRKD2FYNMAP4K4 | |
| SCHEMBL1679782 | 0.92 | PRKD3 (0.69) | PRKD3PRKD1PRKD2FYNMAP4K4 | |
| SCHEMBL1679497 | 0.92 | PRKD3 (0.69) | PRKD3PRKD1PRKD2FYNMAP4K4 | |
| SCHEMBL1679694 | 0.90 | PRKD3 (0.71) | PRKD3PRKD1PRKD2FYNMAP4K4 | |
| SCHEMBL1679127 | 0.90 | PRKD3 (0.67) | PRKD3PRKD1PRKD2FYNMAP4K4 | |
| SCHEMBL1679095 | 0.90 | PRKD3 (0.69) | PRKD3PRKD1PRKD2FYNMAP4K4 | |
| SCHEMBL1679754 | 0.90 | PRKD3 (0.69) | PRKD3PRKD1PRKD2FYNMAP4K4 | |
| SCHEMBL1679461 | 0.89 | PRKD3 (0.65) | PRKD3PRKD1PRKD2FYNMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | claimed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| WO-2008074997-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | PKD2, PKD1, BAZ2B | PRKD3 38/4885PRKD1 33/4885PRKD2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.